Clinical trials · California
HER2 + Breast Cancer clinical trials in California
We’re tracking 119 recruiting her2 + breast cancer studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
La Jolla, CaliforniaAges 18 years+ - NCT06445738Recruiting
Can some women safely skip radiation after breast cancer surgery?
This trial is for women 50 and older with early-stage, hormone-positive or HER2-positive breast cancer. It tests whether it is safe to skip radiation therapy after a lumpectomy if an MRI before surgery shows the breast tissue looks a certain way.
San Francisco, CaliforniaAges 50 years+ - NCT06471673RecruitingPhase 1/Phase 2
BRIA-OTS cellular immunotherapy for metastatic breast cancer
This study tests an investigational cellular immunotherapy called BRIA-OTS for people with metastatic breast cancer that has spread and is no longer responding to standard treatments. It aims to help the immune system fight cancer cells.
Santa Monica, CaliforniaAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
San Francisco, CaliforniaAges 18 years+ - NCT06568692RecruitingPhase 2
Study of PCS6422 with capecitabine for advanced breast cancer
This trial tests a new drug combination (PCS6422 plus capecitabine) for people with advanced or metastatic breast cancer that has not responded to other treatments. The goal is to see if adding PCS6422 can make the chemotherapy work better.
Oxnard, CaliforniaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
San Francisco, CaliforniaAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant vs standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
Bakersfield, CaliforniaAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Los Angeles, CaliforniaAges 18 years+ - NCT06764940RecruitingPhase 2
Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Duarte, CaliforniaAges 18 years+ - NCT06774027Recruiting
Breast cancer antibody-drug conjugate treatment registry
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06896474Recruiting
Breast cancer treatment choice help for women 70 and older
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
Los Angeles, CaliforniaAges 18 years+ - NCT06966453RecruitingPhase 1/Phase 2
Study of disitamab vedotin for HER2-positive advanced breast cancer
This study tests a new drug called disitamab vedotin for people with advanced breast cancer that has a certain amount of HER2 protein. Depending on your HER2 and hormone receptor status, you may be eligible for one of three groups, each with different prior treatment requirements.
Anaheim, CaliforniaAges 18 years+ - NCT07007559RecruitingPhase 2
Evorpacept with trastuzumab and chemo for HER2+ breast cancer
This trial tests a new drug called evorpacept combined with trastuzumab (Herceptin) and a chemotherapy drug of your choice. It is for people with HER2-positive breast cancer that has spread and who have already tried the drug Enhertu.
Duarte, CaliforniaAges 18 years+ - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07054190RecruitingPhase 2
Testing Inavolisib in early-stage breast cancer with PIK3CA mutation
This trial is testing a drug called Inavolisib (a type of targeted therapy) given before surgery for people with early-stage, hormone receptor-positive, HER2-negative breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding Inavolisib to standard endocrine therapy can shrink the tumor more effectively.
Los Angeles, CaliforniaAges 18 years+ - NCT07211178Recruiting
Tracking cancer DNA in blood to detect early return of breast cancer
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
Whittier, CaliforniaAges 18–99 - NCT07227233RecruitingPhase 2
AI-guided retrial of CDK4/6 inhibitors for advanced breast cancer
This trial tests whether an artificial intelligence (AI) tool can help doctors decide if it is safe and effective to give you a second course of a CDK4/6 inhibitor drug (like palbociclib, ribociclib, or abemaciclib) plus hormone therapy for advanced (unresectable or metastatic) HR+/HER2- breast cancer. The goal is to only treat people whose cancer is likely to respond based on a special AI analysis of their tumor tissue.
La Jolla, CaliforniaAges 18 years+ - NCT07558733RecruitingPhase 1/Phase 2
New drug combinations for advanced hormone-receptor positive breast cancer
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07524322RecruitingPhase 1
RGT-490 for Advanced Cancers With PIK3CA Mutations
This study tests a new drug called RGT-490 in patients with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have a specific genetic change called a PIK3CA mutation. The drug is designed to block a protein involved in cancer cell growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05376878RecruitingPhase 4
PET/MRI scan to guide treatment in HER2+ brain metastatic breast cancer
This trial tests a special PET/MRI imaging scan using a labeled drug to help doctors evaluate HER2+ breast cancer that has spread to the brain. It focuses on patients who plan to receive fam-trastuzumab deruxtecan, a targeted cancer medicine, and aims to see how well the scan can support treatment decisions.
Duarte, CaliforniaAges 18 years+ - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
San Francisco, CaliforniaAges 18 years+ - NCT01766297RecruitingPhase 2
Proton radiation after lumpectomy for early breast cancer
This trial studies a type of radiation made with protons to treat only part of the breast after surgery (lumpectomy) for early-stage breast cancer. It may help control the cancer while aiming to reduce radiation to surrounding tissues.
San Diego, CaliforniaAges 50 years+ - NCT05645536Enrolling by invitationPhase 3
Safety follow-up for hormone-positive, HER2-negative breast cancer
This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.
Greenbrae, CaliforniaAges 18–51
HER2 + Breast Cancer trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting her2 + breast cancer studies listed above.
- City of Hope Comprehensive Cancer Center · 9 studies
- University of California, Los Angeles (UCLA) · 5 studies
- University of California, San Francisco · 5 studies
- UC San Diego Moores Cancer Center · 3 studies
- University of California San Diego Health · 3 studies
- City of Hope Orange County Lennar Foundation Cancer Center · 2 studies
- Hoag Memorial Hospital Presbyterian · 2 studies
- Los Angeles Cancer Network · 2 studies
What taking part in a her2 + breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
HER2 + Breast Cancer trials in other states
Common questions
- Are there her2 + breast cancer clinical trials in California?
- Yes. We're currently tracking 119 recruiting her2 + breast cancer studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a her2 + breast cancer study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a her2 + breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New her2 + breast cancer studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.